Boehringer Ingelheim International Gmbh

Bayer Intellectual Property Gmbh

Stephen James Boyer

Xin Guo

Thomas Martin Kirrane, Jr

Roger John Snow

Yunlong Zhang

Manoj Patel

Karl-Heinz Thierauch

Hartmut Beck

Christopher Ronald Sarko

Michael Härter

Donghong Amy Gao

Holger Hess-Stumpp

Fariba Soleymanzadeh

Susanne Greschat

Jennifer Burke

Frank Wu

Peter Ellinghaus

Di Wu

Ellalahewage Sathyajith Kumarasinghe

Philip Wickens

Ajay Kumar Bhargava

Patrick Paulus

Thomas Martin Kirrane Jr

Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

Heterocyclic compounds containing an indole core

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R, R, R, R, Rand n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core

This invention relates to novel heteroaryl substituted pyrazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients or therapeutic measures.

Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Mineralocorticoid receptor antagonists, of which the following is exemplary. 

Mineralocorticoid receptor antagonists

Growing community of inventors

Bethany, CT, United States of America

Stephen James Boyer